세계의 바이오마커 탐색 아웃소싱 시장 : 산업 분석, 시장 규모, 점유율, 성장 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the global Biomarker Discovery Outsourcing Services Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Biomarker Discovery Outsourcing Services Market Size (2025E): US$ 14.8 Bn
• Projected Market Value (2032F): US$ 38.4 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 14.5%

Biomarker Discovery Outsourcing Services Market - Report Scope:

The biomarker discovery outsourcing services market refers to the outsourcing of specialized services to identify and validate biological markers used in drug development and disease diagnosis. This includes services related to biomarker identification, validation, profiling, and selection, often utilized by pharmaceutical and biotechnology companies. As the complexity of drug development increases, companies are increasingly turning to contract research organizations (CROs) and external service providers to access advanced technologies and expertise, reduce costs, and accelerate timelines. The rising demand for personalized medicine, the surge in chronic diseases, and the need for efficient clinical trials are accelerating the growth of this market.

Market Growth Drivers:

The market is witnessing significant growth due to several key drivers. The increasing prevalence of chronic and complex diseases such as cancer, cardiovascular, and neurological disorders has heightened the need for precision medicine, which relies heavily on biomarker discovery. Pharmaceutical and biotechnology companies are under pressure to enhance drug development efficiency, pushing them to outsource complex biomarker research to reduce time and cost. Technological advancements in genomics, proteomics, and bioinformatics have made it easier to identify novel biomarkers, further stimulating market demand. Additionally, the regulatory support for biomarker-based clinical trials and drug approvals is encouraging investment in outsourced biomarker discovery services.

Market Restraints:

Despite robust growth prospects, the biomarker discovery outsourcing services market faces several challenges. High service costs and the complexity of biomarker validation processes can deter small and mid-sized enterprises from outsourcing. Data security concerns and intellectual property (IP) risks also pose significant barriers, especially in cross-border collaborations. Moreover, a shortage of skilled professionals and limited standardization in biomarker research methodologies can impact service quality and reproducibility, potentially affecting clinical outcomes. Variability in regulatory frameworks across regions may further hinder seamless outsourcing operations and market expansion.

Market Opportunities:

The market presents significant opportunities as demand for personalized therapies and precision diagnostics grows globally. Increasing R&D investments by pharmaceutical and biotech firms in developing targeted therapies are expected to boost outsourcing needs. Emerging markets in Asia-Pacific and Latin America offer untapped potential due to a rising patient base, growing healthcare infrastructure, and cost advantages. The integration of artificial intelligence (AI) and machine learning (ML) in biomarker analysis opens new avenues for innovation, enhancing discovery speed and accuracy. Strategic partnerships, mergers, and acquisitions among CROs and pharmaceutical companies can further accelerate market growth by expanding capabilities and service portfolios.

Key Questions Answered in the Report:

• What are the primary factors driving the global biomarker discovery outsourcing services market's growth?
• Which therapeutic areas and discovery phases are seeing the highest demand for outsourced services?
• How are technological advancements in genomics and AI influencing market dynamics?
• Who are the key players in the biomarker discovery outsourcing services market, and what strategies are they adopting?
• What are the emerging trends and future projections for the global biomarker discovery outsourcing services market?

Competitive Intelligence and Business Strategy:

Leading companies in the global biomarker discovery outsourcing services market, such as Laboratory Corporation of America Holdings, Celerion, Charles River Laboratories, and Thermo Fisher Scientific Inc., are focusing on expanding their biomarker service offerings and enhancing technological capabilities. Strategic collaborations with pharmaceutical firms and acquisitions of niche CROs are common strategies to gain a competitive edge. These companies are also investing in AI-powered analytics platforms and multi-omics approaches to improve biomarker identification and validation. By strengthening global laboratory networks and ensuring compliance with evolving regulatory standards, these players aim to meet growing industry demands efficiently.

Companies Covered in This Report:

• Laboratory Corporation of America Holdings
• Celerion
• Charles River Laboratories
• Eurofins Scientific
• GHO Capital
• ICON plc
• Evotec
• Parexel International (MA) Corporation
• Thermo Fisher Scientific Inc.
• Proteome Sciences

Market Segmentation:

By Biomarker Type:

• Predictive Biomarkers
• Prognostic Biomarkers
• Safety Biomarkers
• Surrogate Biomarkers

By Therapeutic Area:

• Oncology
• Cardiology
• Neurology
• Autoimmune Diseases
• Others

By Discovery Phase:

• Biomarker Identification
• Biomarker Validation
• Biomarker Profiling
• Biomarker Panel Development
• Biomarker Selection

By End-use:

• Pharmaceutical Companies
• Biotechnology Companies
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Biomarker Discovery Outsourcing Services Market Snapshot, 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-economic Factors
  • 2.3.1. Impact of International Trade Policies on Analytical Instruments
  • 2.3.2. Economic Recovery and Increased Research Spending in Healthcare
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Biomarker Type Demand Analysis
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Biomarker Discovery Outsourcing Services Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Volume (Units) Projections
  • 4.1.2. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.3. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Biomarker Discovery Outsourcing Services Market Outlook: Biomarker Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Biomarker Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 4.3.3.1. Predictive Biomarkers
    • 4.3.3.2. Prognostic Biomarkers
    • 4.3.3.3. Safety Biomarkers
    • 4.3.3.4. Surrogate Biomarkers
  • 4.3.4. Market Attractiveness Analysis: Biomarker Type
• 4.4. Global Biomarker Discovery Outsourcing Services Market Outlook: Therapeutic Area
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
    • 4.4.3.1. Oncology
    • 4.4.3.2. Cardiology
    • 4.4.3.3. Neurology
    • 4.4.3.4. Autoimmune Diseases
    • 4.4.3.5. Others
  • 4.4.4. Market Attractiveness Analysis: Therapeutic Area
• 4.5. Global Biomarker Discovery Outsourcing Services Market Outlook: Discovery Phase
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Discovery Phase, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
    • 4.5.3.1. Biomarker Identification
    • 4.5.3.2. Biomarker Validation
    • 4.5.3.3. Biomarker Profiling
    • 4.5.3.4. Biomarker Panel Development
    • 4.5.3.5. Biomarker Selection
  • 4.5.4. Market Attractiveness Analysis: Discovery Phase
• 4.6. Global Biomarker Discovery Outsourcing Services Market Outlook: End Use
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2024
  • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
    • 4.6.3.1. Pharmaceutical Companies
    • 4.6.3.2. Biotechnology Companies
    • 4.6.3.3. Others
  • 4.6.4. Market Attractiveness Analysis: End Use

5. Global Biomarker Discovery Outsourcing Services Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Biomarker Discovery Outsourcing Services Market Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Biomarker Type
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By Discovery Phase
  • 6.2.5. By End Use
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 6.4.1.
    • 6.4.1.1.
      • 6.4.1.1.1. Predictive Biomarkers
      • 6.4.1.1.2. Prognostic Biomarkers
      • 6.4.1.1.3. Safety Biomarkers
      • 6.4.1.1.4. Surrogate Biomarkers
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 6.5.1. Oncology
  • 6.5.2. Cardiology
  • 6.5.3. Neurology
  • 6.5.4. Autoimmune Diseases
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 6.6.1. Biomarker Identification
  • 6.6.2. Biomarker Validation
  • 6.6.3. Biomarker Profiling
  • 6.6.4. Biomarker Panel Development
  • 6.6.5. Biomarker Selection
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 6.7.1. Pharmaceutical Companies
  • 6.7.2. Biotechnology Companies
  • 6.7.3. Others
• 6.8. Market Attractiveness Analysis

7. Europe Biomarker Discovery Outsourcing Services Market Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Biomarker Type
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Discovery Phase
  • 7.2.5. By End Use
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 7.4.1.
    • 7.4.1.1.
      • 7.4.1.1.1. Predictive Biomarkers
      • 7.4.1.1.2. Prognostic Biomarkers
      • 7.4.1.1.3. Safety Biomarkers
      • 7.4.1.1.4. Surrogate Biomarkers
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 7.5.1. Oncology
  • 7.5.2. Cardiology
  • 7.5.3. Neurology
  • 7.5.4. Autoimmune Diseases
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 7.6.1. Biomarker Identification
  • 7.6.2. Biomarker Validation
  • 7.6.3. Biomarker Profiling
  • 7.6.4. Biomarker Panel Development
  • 7.6.5. Biomarker Selection
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 7.7.1. Pharmaceutical Companies
  • 7.7.2. Biotechnology Companies
  • 7.7.3. Others
• 7.8. Market Attractiveness Analysis

8. East Asia Biomarker Discovery Outsourcing Services Market Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Biomarker Type
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Discovery Phase
  • 8.2.5. By End Use
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 8.4.1.
    • 8.4.1.1.
      • 8.4.1.1.1. Predictive Biomarkers
      • 8.4.1.1.2. Prognostic Biomarkers
      • 8.4.1.1.3. Safety Biomarkers
      • 8.4.1.1.4. Surrogate Biomarkers
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 8.5.1. Oncology
  • 8.5.2. Cardiology
  • 8.5.3. Neurology
  • 8.5.4. Autoimmune Diseases
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 8.6.1. Biomarker Identification
  • 8.6.2. Biomarker Validation
  • 8.6.3. Biomarker Profiling
  • 8.6.4. Biomarker Panel Development
  • 8.6.5. Biomarker Selection
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 8.7.1. Pharmaceutical Companies
  • 8.7.2. Biotechnology Companies
  • 8.7.3. Others
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Biomarker Discovery Outsourcing Services Market Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Biomarker Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Discovery Phase
  • 9.2.5. By End Use
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 9.4.1.
    • 9.4.1.1.
      • 9.4.1.1.1. Predictive Biomarkers
      • 9.4.1.1.2. Prognostic Biomarkers
      • 9.4.1.1.3. Safety Biomarkers
      • 9.4.1.1.4. Surrogate Biomarkers
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 9.5.1. Oncology
  • 9.5.2. Cardiology
  • 9.5.3. Neurology
  • 9.5.4. Autoimmune Diseases
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 9.6.1. Biomarker Identification
  • 9.6.2. Biomarker Validation
  • 9.6.3. Biomarker Profiling
  • 9.6.4. Biomarker Panel Development
  • 9.6.5. Biomarker Selection
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 9.7.1. Pharmaceutical Companies
  • 9.7.2. Biotechnology Companies
  • 9.7.3. Others
• 9.8. Market Attractiveness Analysis

10. Latin America Biomarker Discovery Outsourcing Services Market Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Biomarker Type
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Discovery Phase
  • 10.2.5. By End Use
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 10.4.1.
    • 10.4.1.1.
      • 10.4.1.1.1. Predictive Biomarkers
      • 10.4.1.1.2. Prognostic Biomarkers
      • 10.4.1.1.3. Safety Biomarkers
      • 10.4.1.1.4. Surrogate Biomarkers
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 10.5.1. Oncology
  • 10.5.2. Cardiology
  • 10.5.3. Neurology
  • 10.5.4. Autoimmune Diseases
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 10.6.1. Biomarker Identification
  • 10.6.2. Biomarker Validation
  • 10.6.3. Biomarker Profiling
  • 10.6.4. Biomarker Panel Development
  • 10.6.5. Biomarker Selection
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 10.7.1. Pharmaceutical Companies
  • 10.7.2. Biotechnology Companies
  • 10.7.3. Others
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Biomarker Discovery Outsourcing Services Market Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Biomarker Type
  • 11.2.3. By Therapeutic Area
  • 11.2.4. By Discovery Phase
  • 11.2.5. By End Use
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 11.4.1.
    • 11.4.1.1.
      • 11.4.1.1.1. Predictive Biomarkers
      • 11.4.1.1.2. Prognostic Biomarkers
      • 11.4.1.1.3. Safety Biomarkers
      • 11.4.1.1.4. Surrogate Biomarkers
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
  • 11.5.1. Oncology
  • 11.5.2. Cardiology
  • 11.5.3. Neurology
  • 11.5.4. Autoimmune Diseases
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
  • 11.6.1. Biomarker Identification
  • 11.6.2. Biomarker Validation
  • 11.6.3. Biomarker Profiling
  • 11.6.4. Biomarker Panel Development
  • 11.6.5. Biomarker Selection
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
  • 11.7.1. Pharmaceutical Companies
  • 11.7.2. Biotechnology Companies
  • 11.7.3. Others
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Laboratory Corporation of America Holdings
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Biomarker Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Celerion
  • 12.3.3. Charles River Laboratories
  • 12.3.4. Eurofins Scientific
  • 12.3.5. GHO Capital
  • 12.3.6. ICON plc
  • 12.3.7. Evotec
  • 12.3.8. Parexel International (MA) Corporation
  • 12.3.9. Thermo Fisher Scientific Inc.
  • 12.3.10. Proteome Sciences
  • 12.3.11. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations